Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses.
作者信息
López Daniel, García-Peydró Marina
机构信息
Presentation and Immune Regulation Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), Madrid, Spain.
出版信息
Front Immunol. 2023 Dec 12;14:1118267. doi: 10.3389/fimmu.2023.1118267. eCollection 2023.
Abstract
摘要
相似文献
1
Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses.
Front Immunol. 2023 Dec 12;14:1118267. doi: 10.3389/fimmu.2023.1118267. eCollection 2023.
2
A survey of ORF8 sequence and immunoinformatics features during alpha, delta, and wild type peaks of the SARS-CoV-2 pandemic in Iran.
Malawi Med J. 2023 Jun;35(2):101-105. doi: 10.4314/mmj.v35i2.5.
3
Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
Immunobiology. 2020 May;225(3):151955. doi: 10.1016/j.imbio.2020.151955. Epub 2020 May 11.
4
Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Infect Dis Poverty. 2020 Sep 16;9(1):132. doi: 10.1186/s40249-020-00752-w.
5
A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
Front Immunol. 2021 Feb 26;12:598778. doi: 10.3389/fimmu.2021.598778. eCollection 2021.
6
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review.
J Transl Med. 2020 Sep 21;18(1):358. doi: 10.1186/s12967-020-02534-2.
7
SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.
Travel Med Infect Dis. 2020 Sep-Oct;37:101830. doi: 10.1016/j.tmaid.2020.101830. Epub 2020 Aug 2.
8
COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.
Altern Ther Health Med. 2020 Aug;26(S2):56-64.
9
COVID-19 Highlights the Need for More Effective Wildlife Trade Legislation.
Trends Ecol Evol. 2020 Dec;35(12):1052-1055. doi: 10.1016/j.tree.2020.10.001. Epub 2020 Oct 7.
10
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection.
Emerg Infect Dis. 2023 Feb;29(2):381-388. doi: 10.3201/eid2902.221422.
引用本文的文献
1
Bioinformatic Tools for Studying the Cellular Immune Response to SARS-CoV-2, Vaccine Efficacy, and Future Pandemics at the Global Population Level.
Int J Mol Sci. 2024 Dec 16;25(24):13477. doi: 10.3390/ijms252413477.
本文引用的文献
1
Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.
Biomedicines. 2022 Jul 7;10(7):1622. doi: 10.3390/biomedicines10071622.
2
Cross-protective immunity following coronavirus vaccination and coronavirus infection.
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI151969.
3
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23.
4
Vaccination and the TAP-independent antigen processing pathways.
Expert Rev Vaccines. 2013 Sep;12(9):1077-83. doi: 10.1586/14760584.2013.825447.
5
Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
Viral Immunol. 2013 Apr;26(2):126-32. doi: 10.1089/vim.2012.0076.
6
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26.
7
Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
Antivir Ther. 2007;12(7):1107-13.
8
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
J Virol. 2006 Jun;80(12):5757-67. doi: 10.1128/JVI.00083-06.
9
Trial watch: SARS vaccine enters Phase I trials.
Expert Rev Vaccines. 2004 Aug;3(4):386.
10
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6. doi: 10.1073/pnas.0401939101. Epub 2004 Apr 19.
Zotero 插件